In the 2022/2023 business year, the company’s product portfolio consisted of 653 products
Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries. More

To Lead a Long and Healthy Life

Health means more than just the lack of illnesses.


Over 2 million vitamin capsules for families in need

Egis has donated 50,000 boxes of vitamin C capsules to Hungarian families coping with difficulties. The donations were taken by the Children’s Food Foundation to residents in underdeveloped regions under the “Pharmacy for the Poor” programme.


Egis Attends Heart Day

Egis attended the event with a fork lift truck simulator that playfully presented the firm’s therapeutic areas.

WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox